Intravenous immunoglobulin therapy in rheumatic diseases (Q37873722)

24 August 2017

1 reference

title

Intravenous immunoglobulin therapy in rheumatic diseases (English)

1 reference

24 August 2017

Srini V Kaveri

3

0 references

Jagadeesh Bayry

object named as

Jagadeesh Bayry

series ordinal

1

0 references

author name string

Vir Singh Negi

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

10 May 2011

1 reference

Nature Reviews Rheumatology

24 August 2017

published in

1 reference

24 August 2017

volume

7

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

349-359

1 reference

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Gene Expression Profiling of the Effect of High-Dose Intravenous Ig in Patients with Kawasaki Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

FOXP3+ regulatory T cells in the human immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Regulatory T cells as therapeutic targets in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Autoimmunity: CTLA-4: a key protein in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Type 17 T helper cells-origins, features and possible roles in rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Resistance to intravenous immunoglobulin in children with Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Infliximab treatment for refractory Kawasaki syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Classification and treatment of the juvenile idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Skin involvement in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Immunotherapy of myositis: issues, concerns and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Immunologic rheumatic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

ANCA-associated vasculitides--advances in pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Basophils and the T helper 2 environment can promote the development of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Pathogenesis of human systemic lupus erythematosus: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Basophils and nephritis in lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

T cells as therapeutic targets in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin up-regulates the expression of the inhibitory FcgammaIIB receptor on B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Modulation of the cellular immune system by intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

What is the contents of the magic draft IVIg?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Antiphospholipid syndrome: frequency, main causes and risk factors of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Cellular and molecular aspects of vascular dysfunction in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Fibrosis regression induced by intravenous gammaglobulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Identification of a receptor required for the anti-inflammatory activity of IVIG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

The antiinflammatory IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Anti-inflammatory actions of intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Safety of intravenous immunoglobulin (IVIG) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Rituximab and intravenous immune globulin for desensitization during renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Induction of remission with intravenous immunoglobulin and cyclophosphamide in steroid-resistant Evans' syndrome associated with dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Adverse events associated with intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Soluble type A substance in fresh-frozen plasma as a function of ABO and Secretor genotypes and Lewis phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-? present in serum from patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Shortage of human intravenous immunoglobulin—reasons and possible solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin for the treatment of Kawasaki disease in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Catastrophic antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. IV immunoglobulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Dermatomyositis: Remission Induced With Combined Oral Cyclosporine and High-Dose Intravenous Immune Globulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

The clinical features of 16 cases of stroke associated with administration of IVIg

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.61

Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group.

31 March 2020

1 reference

12 December 2020

Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.

1 reference

12 December 2020

High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients.

1 reference

12 December 2020

Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy.

1 reference

12 December 2020

Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2011.61

1 reference

24 August 2017

1 reference